Loading
NASDAQHealthcareBiotechnology
Latest quote
$5.13
+$0.12 · +2.40%
Aardvark Therapeutics, Inc. is a biopharmaceutical firm in its clinical development phase, concentrating on developing small-molecule treatments. These therapies are designed to stimulate the body's natural regulatory systems (innate homeostatic pathways) to combat metabolic disorders. The company's primary experimental drug, ARD-101, is an orally administered, gut-specific small molecule. It functions as an agonist, targeting particular bitter taste receptors found within the gut lumen. ARD-101 is currently undergoing a Phase III clinical trial for managing excessive hunger (hyperphagia) associated with Prader-Willi Syndrome. Additionally, it is in a Phase II trial for addressing hyperphagia linked to acquired hypothalamic obesity, often a result of craniopharyngioma treatments like surgery or radiation therapy. Aardvark Therapeutics is also advancing ARD-201, which is currently in Phase I clinical trials for the treatment of obesity. Established in 2017, the company is based in San Diego, California.
Previous close
$5.13
+$0.12 · +2.40%
Regular session · ET · Market data may be delayed.
Aardvark Therapeutics, Inc. is a biopharmaceutical firm in its clinical development phase, concentrating on developing small-molecule treatments. These therapies are designed to stimulate the body's natural regulatory systems (innate homeostatic pathways) to combat metabolic disorders. The company's primary experimental drug, ARD-101, is an orally administered, gut-specific small molecule. It functions as an agonist, targeting particular bitter taste receptors found within the gut lumen. ARD-101 is currently undergoing a Phase III clinical trial for managing excessive hunger (hyperphagia) associated with Prader-Willi Syndrome. Additionally, it is in a Phase II trial for addressing hyperphagia linked to acquired hypothalamic obesity, often a result of craniopharyngioma treatments like surgery or radiation therapy. Aardvark Therapeutics is also advancing ARD-201, which is currently in Phase I clinical trials for the treatment of obesity. Established in 2017, the company is based in San Diego, California.
Day range
Current $5.13
52-week range
Current $5.13
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
31
Expensive
Sentiment
41
Mixed
Risk
93
Extreme Risk
Momentum
54
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Aardvark Therapeutics, Inc. is a biopharmaceutical firm in its clinical development phase, concentrating on developing small-molecule treatments. These therapies are designed to stimulate the body's natural regulatory systems (innate homeostatic pathways) to combat metabolic disorders. The company's primary experimental drug, ARD-101, is an orally administered, gut-specific small molecule. It functions as an agonist, targeting particular bitter taste receptors found within the gut lumen. ARD-101 is currently undergoing a Phase III clinical trial for managing excessive hunger (hyperphagia) associated with Prader-Willi Syndrome. Additionally, it is in a Phase II trial for addressing hyperphagia linked to acquired hypothalamic obesity, often a result of craniopharyngioma treatments like surgery or radiation therapy. Aardvark Therapeutics is also advancing ARD-201, which is currently in Phase I clinical trials for the treatment of obesity. Established in 2017, the company is based in San Diego, California.
Day range
Current $5.13
52-week range
Current $5.13
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Research and development | 48.94M USD | 17.36M USD | 4.48M USD | 7.17M USD |
| Selling, general, and administrative | 13.79M USD | 5.31M USD | 2.17M USD | 2.7M USD |
| Operating expenses | 62.73M USD | 22.79M USD | 7.42M USD | 11.36M USD |
| Interest income | 5.14M USD | 2.41M USD | 1.42M USD | 120K USD |
| Depreciation and amortization | 36K USD | 16K USD | 97K USD | 110K USD |
| Operating income | −62.73M USD | −22.79M USD | −7.42M USD | −11.36M USD |
| Net income | −57.59M USD | −20.59M USD | −7.21M USD | −13.56M USD |
Company facts updated Sep 13, 2026.
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$3.00
41.52% downsideFunds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI2.7M0.00%2.3T USD0.03%$376.31+0.82%
Vanguard Extended Market ETFVXF926.57K0.00%93.7B USD0.05%$237.76+0.68%
iShares Biotechnology ETFIBB465.94K0.00%10.3B USD0.44%$202.93+0.14%
iShares Micro-Cap ETFIWC220.24K0.02%1.44B USD0.60%$190.84+0.39%
Invesco Nasdaq Biotechnology ETFIBBQ6.91K0.01%95.74M USD0.19%$34.472+0.09%
U.S. Micro Cap Portfolio ETFDFMC6.12K0.00%7.73B USD0.43%$59.13+0.67%
ProShares Ultra Nasdaq BiotechnologyBIB3.76K0.00%95.43M USD1.19%$109.77+0.16%
Avantis U.S. Small Cap Equity ETFAVSC2.1K—3.09B USD0.25%$71.48+0.53%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Biotechnology ETFIBBiShares Micro-Cap ETFIWCInvesco Nasdaq Biotechnology ETFIBBQU.S. Micro Cap Portfolio ETFDFMCProShares Ultra Nasdaq BiotechnologyBIBAvantis U.S. Small Cap Equity ETFAVSCAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
